Candriam SCA Portfolio holdings
Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$98.2M |
| 2 |
Meta Platforms (Facebook)
META
|
+$82.9M |
| 3 |
ServiceNow
NOW
|
+$70.4M |
| 4 |
Intel
INTC
|
+$58.4M |
| 5 |
Salesforce
CRM
|
+$54.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$102M |
| 2 |
Palo Alto Networks
PANW
|
+$102M |
| 3 |
AbbVie
ABBV
|
+$68.9M |
| 4 |
Amazon
AMZN
|
+$57M |
| 5 |
NVIDIA
NVDA
|
+$54.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.06% |
| 2 | Healthcare | 24.01% |
| 3 | Financials | 9.02% |
| 4 | Communication Services | 7.08% |
| 5 | Consumer Discretionary | 6.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Procter & Gamble
PG
$389B
| $86.1M | 0.38% |
590,173
-66,250
| -10% | -$9.7M |
2014 Q4
47 quarters
|
|
52
Cisco
CSCO
$397B
| $84.8M | 0.38% |
784,749
-31,106
| -4% | -$3.5M |
2014 Q4
47 quarters
|
|
53
Keysight
KEYS
$52B
| $84.6M | 0.38% |
231,655
+3,229
| +1% | +$1.06M |
2019 Q1
30 quarters
|
|
54
Veeva Systems
VEEV
$49.3B
| $82.5M | 0.37% |
287,807
-1,918
| -0.7% | -$451K |
2018 Q3
32 quarters
|
|
55
Emerson Electric
EMR
$93.2B
| $81.4M | 0.36% |
522,744
-775
| -0.1% | -$117K |
2014 Q4
47 quarters
|
|
56
Intercontinental Exchange
ICE
$101B
| $80.4M | 0.36% |
526,931
+156,639
| +42% | +$23.7M |
2014 Q4
47 quarters
|
|
57
S&P Global
SPGI
$138B
| $77M | 0.34% |
194,583
+29,806
| +18% | +$12.6M |
2016 Q2
41 quarters
|
|
58
Rockwell Automation
ROK
$45.1B
| $77M | 0.34% |
176,138
+917
| +0.5% | +$408K |
2014 Q4
47 quarters
|
|
59
Bristol-Myers Squibb
BMY
$129B
| $76.6M | 0.34% |
1,223,695
+27,623
| +2% | +$1.75M |
2014 Q4
47 quarters
|
|
60
Alnylam Pharmaceuticals
ALNY
$21.4B
| $76M | 0.34% |
306,933
-7,579
| -2% | -$1.93M |
2014 Q4
47 quarters
|
|
61
Costco
COST
$482B
| $75.6M | 0.34% |
82,716
+30,899
| +60% | +$28.8M |
2014 Q4
47 quarters
|
|
62
Applied Materials
AMAT
$314B
| $75M | 0.33% |
146,209
+59,199
| +68% | +$30.1M |
2016 Q1
42 quarters
|
|
63
Monolithic Power Systems
MPWR
$72.1B
| $74.7M | 0.33% |
55,245
+340
| +0.6% | +$445K |
2023 Q1
14 quarters
|
|
64
Moderna
MRNA
$101B
| $74.4M | 0.33% |
384,828
+75,632
| +24% | +$8.15M |
2020 Q4
23 quarters
|
|
65
Parker-Hannifin
PH
$123B
| $72.8M | 0.32% |
75,944
+5,016
| +7% | +$4.92M |
2014 Q4
47 quarters
|
|
66
Walt Disney
DIS
$207B
| $69.3M | 0.31% |
657,918
+144,178
| +28% | +$14.8M |
2014 Q4
47 quarters
|
|
67
Grupo Cibest SA
CIB
$21.7B
| $68.4M | 0.3% |
734,456
+233,000
| +46% | +$21.5M |
2025 Q2
5 quarters
|
|
68
Prologis
PLD
$124B
| $67M | 0.3% |
513,882
+12,357
| +2% | +$1.73M |
2014 Q4
47 quarters
|
|
69
Credo Technology Group
CRDO
$26.6B
| $66.6M | 0.3% |
340,739
+13,680
| +4% | +$2.95M |
2025 Q1
6 quarters
|
|
70
Insmed
INSM
$26.5B
| $66.6M | 0.3% |
581,069
+25,938
| +5% | +$3.06M |
2020 Q2
25 quarters
|
|
71
Coca-Cola
KO
$420B
| $65.7M | 0.29% |
760,448
-32,943
| -4% | -$2.86M |
2014 Q4
47 quarters
|
|
72
Pfizer
PFE
$168B
| $64M | 0.28% |
2,236,830
-353,498
| -14% | -$9.4M |
2014 Q4
47 quarters
|
|
73
Charles Schwab
SCHW
$160B
| $64M | 0.28% |
652,046
-169,781
| -21% | -$17.9M |
2014 Q4
47 quarters
|
|
74
argenx
ARGX
$61.5B
| $63.9M | 0.28% |
66,419
-13,701
| -17% | -$12.9M |
2024 Q1
10 quarters
|
|
75
Cogent Biosciences
COGT
$5.12B
| $63M | 0.28% |
1,959,168
-129,201
| -6% | -$4.77M |
2025 Q2
5 quarters
|
|
Similar funds
Candriam SCA's Q3 2026 Portfolio in Review
As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.
- Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
- Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
- Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
- Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
- Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
- Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
- Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.
Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.